ID   CHLA-171
AC   CVCL_6597
SY   CHLA171
DR   Cosmic; 930060
DR   Cosmic; 1019949
DR   IARC_TP53; 23826
DR   Wikidata; Q54812171
RX   PubMed=11212268;
RX   PubMed=11507071;
RX   PubMed=16822308;
RX   PubMed=24792489;
WW   Provider; CCR; -; https://www.cccells.org/dl/NB_Data_Sheets/CHLA-171_Cell_Line_Data_Sheet_COGcell_org.pdf
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; None_reported; -; Zygosity=- (PubMed=11507071).
ST   Source(s): COG
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 8,9
ST   D16S539: 11,12
ST   D18S51: 17,19
ST   D19S433: 14
ST   D21S11: 29,34.2
ST   D2S1338: 21,24
ST   D3S1358: 15
ST   D5S818: 11,12
ST   D7S820: 12,13
ST   D8S1179: 10,14
ST   FGA: 20,26
ST   TH01: 7,8.3
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   8Y5M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 17
//
RX   PubMed=11212268;
RA   Thompson P.M., Maris J.M., Hogarty M.D., Seeger R.C., Reynolds C.P.,
RA   Brodeur G.M., White P.S.;
RT   "Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36
RT   or at other tumor suppressor loci in neuroblastoma.";
RL   Cancer Res. 61:679-686(2001).
//
RX   PubMed=11507071;
RA   Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C.,
RA   Gomer C.J., Triche T.J., Reynolds C.P.;
RT   "Loss of p53 function confers high-level multidrug resistance in
RT   neuroblastoma cell lines.";
RL   Cancer Res. 61:6185-6193(2001).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177; PMCID=PMC1533846;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//